Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.44 |
| ▸ | GUSB | P08236 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26807214 | 1.00 | CYP19A1 (0.67) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL4885211 | 1.00 | CYP19A1 (0.67) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL32677703 | 1.00 | CYP19A1 (0.67) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL28117691 | 0.90 | CYP19A1 (0.56) | CYP19A1CYP1B1 | |
| SCHEMBL1316417 | 0.82 | CYP19A1 (0.45) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL4448210 | 0.82 | CYP17A1 (0.46) | CYP19A1MEN1LMNASHBGSERPINA6 | |
| SCHEMBL1316415 | 0.82 | CYP19A1 (0.45) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL19818388 | 0.81 | CYP17A1 (0.65) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL29688903 | 0.81 | CYP17A1 (0.65) | CYP19A1CYP1B1MEN1LMNASHBG | |
| SCHEMBL4448216 | 0.81 | CYP19A1 (0.61) | CYP19A1CYP1B1MEN1LMNASHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232021-B1 | SULFATED C19 STEROID HORMONES TO TREAT AND/OR PREVENT PROTEOTOXICITY IN PROTEIN-AGGREGATION DISEASES | UNIV PABLO DE OLAVIDE (ES) | 2026-05-27 | — | — | EP | claimed |
| CN-119595611-A | Method for rapidly detecting androgenic steroid based on surface enhanced Raman scattering technology and application thereof | 上海体育大学 | 2025-03-11 | — | — | CN | claimed |
| US-20230405020-A1 | SULFATED C19 STEROID HORMONES TO TREAT AND/OR PREVENT PROTEOTOXICITY IN PROTEIN-AGGREGATION DISEASES | UNIVERSIDAD PABLO DE OLAVIDE (ES) | 2023-12-21 | — | — | US | claimed |
| CN-116916912-A | Protein toxicity of sulfated C19 steroid hormone for treatment and/or prevention of protein aggregation disease | 帕布罗·德奥拉韦德大学 | 2023-10-20 | — | — | CN | claimed |
| WO-2022149929-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING STEROID SULFATASE INHIBITOR | 연세대학교 산학협력단 | 2022-07-14 | — | — | WO | claimed |
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2022-06-23 | — | — | US | claimed |
| EP-3988096-A1 | SULFATED C19 STEROID HORMONES TO TREAT AND/OR PREVENT PROTEOTOXICITY IN PROTEIN-AGGREGATION DISEASES | Universidad Pablo de Olavide OTRI (ES) | 2022-04-27 | — | — | EP | claimed |
| US-20200237784-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2020-07-30 | — | — | US | claimed |
| US-20160361244-A1 | USE OF THE INHIBITOR OF STEROID SULFATASES STX64 FOR TREATING AGING | UNIVERSIDAD PABLO DE OLAVIDE (ES) | 2016-12-15 | — | — | US | claimed |
| EP-3011950-A1 | USE OF THE INHIBITOR OF STEROID SULFATASES STX64 FOR TREATING AGING | Universidad Pablo de Olavide (ES) | 2016-04-27 | — | — | EP | claimed |
| EP-1083904-A2 | PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3 BETA,17 BETA-DIOL | Endorecherche Inc. (CA) | 2001-03-21 | — | — | EP | claimed |
| WO-2001001969-A2 | METHODS OF TREATING AND/OR SUPPRESSING WEIGHT GAIN | ENDORECHERCHE, INC. (CA) | 2001-01-11 | — | — | WO | claimed |
| WO-2000020007-A1 | METHOD AND COMPOSITIONS FOR INCREASING BONE MASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2000-04-13 | — | — | WO | claimed |
| WO-1999063973-A2 | PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL | ENDORECHERCHE, INC. (CA) | 1999-12-16 | — | — | WO | claimed |
| EP-0633893-B1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BTG INT LTD (GB) | 1999-11-24 | — | — | EP | claimed |
| WO-1998056386-A1 | A MEDICAMENT USEFUL FOR THE TREATMENT OF POST-MENOPAUSAL SYNDROME AND OSTEOPOROSIS, AND FOR REDUCING FAT MASS AND INCREASING LEAN BODY MASS | SUNNIMEX LIMITED (GB) | 1998-12-17 | — | — | WO | claimed |
| JP-2742331-B2 | — | — | 1998-04-22 | — | — | JP | claimed |
| EP-0633893-A1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BRITISH TECHNOLOGY GROUP LTD (GB) | 1995-01-18 | — | — | EP | claimed |
| US-5277907-A | Lymphocyte proliferation-enhancing agent | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-01-11 | — | — | US | claimed |
| WO-1993020097-A1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-10-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | LIPA, LIPC, MGLL | CYP19A1 674/4885CYP1B1 1092/4885MEN1 2842/4885 |
| US-20230405020-A1 | SULFATED C19 STEROID HORMONES TO TREAT AND/OR PREVENT PROTEOTOXICITY IN PROTEIN-AGGREGATION DISEASES | SERPINA6, HTT, PSMG3 | CYP19A1 1368/4885CYP1B1 4014/4885MEN1 1182/4885 |
| US-20200237784-A1 | PHARMACEUTICAL COMPOSITIONS | LIPA, LIPC, MGLL | CYP19A1 674/4885CYP1B1 1092/4885MEN1 2842/4885 |
| US-20160361244-A1 | USE OF THE INHIBITOR OF STEROID SULFATASES STX64 FOR TREATING AGING | STS, CYP17A1, SCLY | CYP19A1 101/4885CYP1B1 877/4885MEN1 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.